GlassScriptPhysician profile
Nuveed Loqman
NPI 1194717439
$1,651.31
in general payments reported to CMS, 2019-2025
22 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $62.51 · 2021: $21.46 · 2022: $16.93 · 2023: $609 · 2024: $250 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $247.71 | 2023-2025 | Wakix |
| Inogen, INC. | $225.22 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.53 | 2022-2025 | Ofev |
| Mallinckrodt Hospital Products INC. | $146.08 | 2024-2025 | Acthar |
| Glaxosmithkline, LLC. | $111.58 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $104.87 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $90.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $87.68 | 2023-2025 | Delstrigo, Dificid |
| Covidien LP | $79.67 | 2019 | |
| Abbvie INC. | $59.75 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $53.52 | 2023-2025 | Uptravi |
| Smith+Nephew, INC. | $47.61 | 2019-2023 | Collagenase Santyl |
| Sunovion Pharmaceuticals INC. | $40.18 | 2019 | |
| 3b Medical, INC. | $30.43 | 2025 | Luna |
| Ani Pharmaceuticals, INC. | $26.07 | 2025 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $25.04 | 2023 | Yupelri |
| Insmed, INC. | $25.00 | 2024 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $22.23 | 2023 | Aralast |
| Electromed, INC. | $21.04 | 2019 | |
| Circassia INC. | $18.12 | 2020 | |
| Allergan, INC. | $17.39 | 2020 | |
| Pfizer INC. | $14.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nuveed Loqman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.